Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved gefurulimab (Klygefa), a once-weekly, self-administered subcutaneous injection for adults with AChR-antibody-positive generalized myasthenia gravis (gMG). It's the first dual-binding nanobody complement C5 inhibitor and the third C5 inhibitor approved for gMG — but the only one patients can administer at home. The approval was backed by the phase 3 PREVAIL trial, which showed meaningful improvements in daily functioning as early as week 1.
The FDA has approved gefurulimab (Klygefa; Alexion/AstraZeneca) for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) — a rare autoimmune disease affecting roughly 98,500 people in the US, about 85% of whom are AChR-positive. Klygefa is the first dual-binding nanobody complement C5 inhibitor: it blocks C5 in the terminal complement cascade while also binding serum albumin to extend its half-life, enabling once-weekly subcutaneous self-injection via autoinjector. This sets it apart from the two previously approved C5 inhibitors — eculizumab (every 2 weeks IV) and ravulizumab (every 8 weeks IV) — both of which require infusion center visits.
The approval was supported by the phase 3 PREVAIL trial, which enrolled 260 adults with AChR-positive gMG. Patients on gefurulimab saw significantly greater improvements in daily functioning and disease severity scores compared to placebo, with benefits emerging as early as week 1 and sustained through 26 weeks and into a 1-year open-label extension. The drug carries a boxed warning for meningococcal infections and is available only through a restricted REMS program.
Key Takeaways:
Why it matters: For patients managing a chronic, often debilitating condition, the ability to self-inject weekly at home — rather than traveling to an infusion center — could meaningfully reduce treatment burden and improve quality of life. As the gMG treatment landscape grows, the field's next challenge is developing better biomarkers to guide personalized therapy selection.